Commodity Channel Index
|Bid||3.5900 x 2900|
|Ask||3.6300 x 900|
|Day's Range||3.4000 - 3.6375|
|52 Week Range||2.7800 - 8.5800|
|Beta (5Y Monthly)||0.93|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for BLUELearn more
Here is your Pro Recap of the biggest analyst picks you may have missed since yesterday: upgrades at Avis Budget, Q2, bluebird bio, Equitrans Midstream, and Financial Services. Avis Budget Group (NASDAQ:CAR) shares gained more than 2% yesterday after Deutsche Bank upgraded the company to Buy from Hold and raised its price target to $263.00 from $239.00, as InvestingPro reported in real time.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Bluebird Bio Inc (NASDAQ: BLUE) has submitted its Biologics License Application (BLA) to the FDA seeking approval for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events (VOEs). The BLA includes a request for Priority Review, which, if granted, would shorten the FDA's review of the application to six months versus a standard review timeline of 10 months. If approved, lovo-cel will be bluebird
Prices for incoming sickle cell disease gene therapies from Vertex Pharmaceuticals Inc (NASDAQ: VRTX)/CRISPR Therapeutics AG (NASDAQ: CRSP), dubbed exagamglogene autotemcel (exa-cel), and Bluebird bio Inc’s (NASDAQ: BLUE) lovotibeglogene autotemcel (lovo-cel) at $2 million could be cost-effective under some scenarios. Although “these gene therapies have an incremental cost-effectiveness that is above commonly cited thresholds from the health care system perspective.” The analysis comes from a U.
With the stock down 52% in the last three months, Bluebird Bio (NASDAQ: BLUE) shareholders are bound to be feeling pretty antsy. Between the company's weak cash position, missed deadline for a drug candidate submission to regulators, and 30% cut in its workforce a year ago, there hasn't been much to celebrate lately. First, while it did miss its goal of submitting its approval packet for a therapy called lovo-cel to the Food and Drug Administration (FDA) in the first quarter, it says that once the FDA gets back to it in a few weeks, it'll do so.
The last 12 months haven't been kind to the likes of gene editing stocks like CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Whereas CRISPR's shares fell by 31%, Bluebird's are down by 33%. CRISPR Therapeutics is on track to have a transformative 2023, but its biggest risk is that regulators will stymie its efforts to commercialize its gene therapy candidate exa-cel, which aims to treat beta thalassemia and sickle cell disease.
Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a question of which of these two biotechs has a higher chance of surviving over the next three years.
Last year was an important one for Bluebird Bio (NASDAQ: BLUE) as the biotech company earned two key regulatory approvals in the U.S. Despite these wins, the market has hardly rewarded the gene-editing specialist; its shares are down 39% in the past year, and Bluebird's market capitalization is currently just $323 million. The company's newly approved therapies are Zynteglo, which targets transfusion-dependent beta-thalassemia (TDT, a rare blood disorder), and Skysona, a medicine for cerebral adrenoleukodystrophy (CALD, a progressive, pediatric, and fatal neurodegenerative disease). The issue here is whether third-party payers will agree to cover these medicines.
Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.
The chief executive of bluebird bio's oncology-focused spinout believes that this year, it will take off as a company in its own right.
Every investor in bluebird bio, Inc. ( NASDAQ:BLUE ) should be aware of the most powerful shareholder groups. And the...
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Just as the Nasdaq Composite (NASDAQINDEX: ^IXIC) led markets lower in 2022, the index is working hard to lead a rebound early in 2023. After being the only one of the three major U.S. stock market indexes to finish higher on Tuesday, the Nasdaq once again looked good early Wednesday morning, with futures on the index rising nearly half a percent. One winner leading the Nasdaq higher Wednesday morning was vaccine stock Moderna (NASDAQ: MRNA), which announced positive news that showed investors the company is more than just a one-trick pony.
After all, many currently well-established companies were once small- or mid-cap stocks. Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled. The company could carry this momentum into this year.
The median annual price of 17 new drugs approved by the FDA since July 2022 reached $193,900, down from $257,000 in 1H of 2022. For the full year 2022, the median price was $222,003. Citing a study published by JAMA, Reuters analysis found that in 2021, the median annual price was $180,000 for the 30 drugs first marketed through mid-July. The analysis includes three recently approved gene therapies, two from Bluebird bio Inc (NASDAQ: BLUE) and one from uniQure N.V. (NASDAQ: QURE). Bluebird's Zyn
In this article, we will discuss the 15 most shorted stocks hedge funds are buying. You can skip our detailed overview and go directly to the 5 Most Shorted Stocks Hedge Funds Are Buying. The year 2022 has been a dynamic year for financial markets worldwide. The equity markets have come under selling pressure across […]
It's been a wild 12 months for biotech company Bluebird Bio (NASDAQ: BLUE). Bluebird earned approval from the U.S. Food and Drug Administration (FDA) for Zynteglo and Skysona in August and September, respectively.
Investors need to pay close attention to bluebird bio (BLUE) stock based on the movements in the options market lately.
The FDA removed its partial clinical hold on Bluebird bio Inc's (NASDAQ: BLUE) study for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel (lovo-cel) for sickle cell disease (SCD). In December 2021, lovo-cel clinical studies were placed on a partial hold for patients under 18. The hold related to an investigation by bluebird bio into an adolescent patient with persistent, non-transfusion-dependent anemia following treatment with lovo-cel. Results from a detailed inves
Bluebird Bio Inc said on Monday that the U.S. health regulator had lifted a partial clinical hold on studies for its gene therapy to treat blood disorder sickle cell disease. The U.S. Food and Drug Administration's decision ends a year-long halt on future studies and a pause in enrollment for ongoing studies of lovo-cel after one case of persistent anemia in a patient. The move also signals a more favorable regulatory environment for cell and gene therapies after a spate of clinical holds by the regulator in the last few years, said SVB Securities analyst Mani Foroohar.
Bluebird Bio (NASDAQ: BLUE) stock got off to a roaring start on Monday, trouncing the S&P 500 index with a nearly 8% gain. The market was cheered by a clinical update and the potential for a new regulatory application in the near future. On Saturday at a healthcare conference, Bluebird presented recent data on its gene therapies for beta-thalassemia and sickle cell disease (SCD).